Biogen

News

Talkiatry co-founders Dr Georgia Gaveras (l) and Robert Krayn (r)

Biogen, Talkiatry team up on postpartum depression

Telehealth company Talkiatry has partnered with Biogen to expand its support service for women who develop postpartum depression (PPD) in a move that could help drive uptake of the latter's

News

football going into the net past goalkeeper to score

UCB, Biogen lupus drug scores in phase 3 trial

UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of

News

UK first country in Europe to clear Leqembi, but NICE says n...

The UK drugs regulator has approved Eisai and Biogen's Alzheimer's disease therapy Leqembi, shortly after an EU committee turned it down on the grounds that its modest efficacy did not outw

News

After EU setback, Eisai/Biogen build case for Leqembi

Eisai and Biogen have reported data showing that the benefit of treatment with their Alzheimer's disease therapy Leqembi appears to build over time, with no increase in safety risks.

News

In shock move, EU panel rejects Alzheimer's drug Leqembi

The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China, and Japan gave a green lig

News

Biogen, Sage drug for essential tremor flunks mid-stage test

Biogen's $3 billion alliance with Sage Therapeutics has suffered another setback after their drug for essential tremor failed to move the needle in a phase 2 study.

Biogen, Talkiatry team up on postpartum depression

UCB, Biogen lupus drug scores in phase 3 trial

UK first country in Europe to clear Leqembi, but NICE says n...

After EU setback, Eisai/Biogen build case for Leqembi

In shock move, EU panel rejects Alzheimer's drug Leqembi

Biogen, Sage drug for essential tremor flunks mid-stage test

FDA points to liver injury with Amgen's Tavneos

Using AI-driven synthetic personas to take your insights fur...

Biogen

Editor's Picks